Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line ...

Retrieved on: 2022-03-05 23:25:53

Tags for this article:

Medical specialties

Clinical medicine

Medicine

Transplantation medicine

Stem cells

Hematology

Surgical oncology

Graft-versus-host disease

Hematopoietic stem cell transplantation

Click the tags to see associated articles and topics

Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line .... View article details on HISWAI: https://pipelinereview.com/index.php/2022030580435/Antibodies/Equillium-Announces-Initiation-of-the-Phase-3-EQUATOR-Study-of-Itolizumab-in-First-line-Acute-Graft-Versus-Host-Disease.html

Excerpt

Details: Category: Antibodies: Published on Saturday, 05 March 2022 18:21 ... Itolizumab, a first-in-class monoclonal antibody that targets the ...

Article found on: pipelinereview.com

View Original Article